FDA Grants Priority Review to Repotrectinib for NTRK+ Solid Tumors
Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.
Source: onclive.com
Repotrectinib Augtyro News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Repotrectinib Augtyro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Repotrectinib Augtyro Today - Breaking & Trending Today
EMA Validates MAA for Repotrectinib in ROS1+ NSCLC and NTRK+ Solid Tumors
The European Medicines Agency has validated its marketing authorization application for repotrectinib in adult patients with ROS1 TKI-naive or -pretreated locally advanced or metastatic non–small cell lung cancer harboring ROS1 fusions, as well as adult and pediatric patients with TKI-naive and pretreated NTRK-positive locally advanced or metastatic solid tumors.
Source: onclive.com
Repotrectinib May Serve as a New Standard of Care Across Treatment Lines in ROS1+ NSCLC
Alexander Drilon, MD, highlights how the approval of repotrectinib addresses the need for improved therapies for patients who have progressed on a previous TKI and delves into notable neurologic toxicities seen with the agent.
Source: onclive.com
Dr Drilon on the Potential Benefit of Taletrectinib in ROS1+ NSCLC
Alexander Drilon, MD, discusses the potential benefit of taletrectinib in patients with ROS1-positive non–small cell lung cancer.
Source: onclive.com
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
Source: onclive.com